Chamberlain JS - Search Results

1

Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.

Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, Nghiem PP, Ahn M, Meng H, Beatka MJ, Fickau BA, Prieto JC, Styner MA, Struharik MJ, Shanks C, Brown KJ, Golebiowski D, Bettis AK, Balog-Alvarez CJ, Clement N, Coleman KE, Corti M, Pan X, Hauschka SD, Gonzalez JP, Morris CA, Schneider JS, Duan D, Chamberlain JS, Byrne BJ, Kornegay JN. Birch SM, et al. Among authors: chamberlain js. Sci Transl Med. 2023 Jan 4;15(677):eabo1815. doi: 10.1126/scitranslmed.abo1815. Epub 2023 Jan 4. Sci Transl Med. 2023. PMID: 36599002 Free PMC article.

2

Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity.

Cox GA, Cole NM, Matsumura K, Phelps SF, Hauschka SD, Campbell KP, Faulkner JA, Chamberlain JS. Cox GA, et al. Among authors: chamberlain js. Nature. 1993 Aug 19;364(6439):725-9. doi: 10.1038/364725a0. Nature. 1993. PMID: 8355788 Free article.

3

Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy.

Hauser MA, Amalfitano A, Kumar-Singh R, Hauschka SD, Chamberlain JS. Hauser MA, et al. Among authors: chamberlain js. Neuromuscul Disord. 1997 Jul;7(5):277-83. doi: 10.1016/s0960-8966(97)00052-7. Neuromuscul Disord. 1997. PMID: 9267841

4

Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.

Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Ahmad A, et al. Among authors: chamberlain js. Hum Mol Genet. 2000 Oct 12;9(17):2507-15. doi: 10.1093/hmg/9.17.2507. Hum Mol Genet. 2000. PMID: 11030755

5

Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS. Harper SQ, et al. Among authors: chamberlain js. Nat Med. 2002 Mar;8(3):253-61. doi: 10.1038/nm0302-253. Nat Med. 2002. PMID: 11875496

6

Progress toward gene therapy of Duchenne muscular dystrophy.

Hartigan-O'Connor D, Chamberlain JS. Hartigan-O'Connor D, et al. Among authors: chamberlain js. Semin Neurol. 1999;19(3):323-32. doi: 10.1055/s-2008-1040848. Semin Neurol. 1999. PMID: 12194388 Review.

7

Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin.

Scott JM, Li S, Harper SQ, Welikson R, Bourque D, DelloRusso C, Hauschka SD, Chamberlain JS. Scott JM, et al. Among authors: chamberlain js. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S23-9. doi: 10.1016/s0960-8966(02)00078-0. Neuromuscul Disord. 2002. PMID: 12206791 Review.

8

Gene therapy of muscular dystrophy.

Chamberlain JS. Chamberlain JS. Hum Mol Genet. 2002 Oct 1;11(20):2355-62. doi: 10.1093/hmg/11.20.2355. Hum Mol Genet. 2002. PMID: 12351570 Review.

9

Gene therapy for muscular dystrophy - a review of promising progress.

Gregorevic P, Chamberlain JS. Gregorevic P, et al. Among authors: chamberlain js. Expert Opin Biol Ther. 2003 Aug;3(5):803-14. doi: 10.1517/14712598.3.5.803. Expert Opin Biol Ther. 2003. PMID: 12880380 Review.

10

Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.

Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Yue Y, et al. Among authors: chamberlain js. Circulation. 2003 Sep 30;108(13):1626-32. doi: 10.1161/01.CIR.0000089371.11664.27. Epub 2003 Sep 2. Circulation. 2003. PMID: 12952841 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page